Akhlaghpour, M.* ; Haritunians, T.* ; More, S.K.* ; Thomas, L.S.* ; Stamps, D.T.* ; Dube, S.* ; Li, D.* ; Yang, S.* ; Landers, C.J.* ; Mengesha, E.* ; Hamade, H.* ; Murali, R.* ; Potdar, A.A.* ; Wolf, A.J.* ; Botwin, G.J.* ; Khrom, M.* ; Ananthakrishnan, A.N.* ; Faubion, W.A.* ; Jabri, B.* ; Lira, S.A.* ; Newberry, R.D.* ; Sandler, R.S.* ; Sartor, R.B.* ; Xavier, R.J.* ; Brant, S.R.* ; Cho, J.H.* ; Duerr, R.H.* ; Lazarev, M.G.* ; Rioux, J.D.* ; Schumm, L.P.* ; Silverberg, M.S.* ; Zaghiyan, K.* ; Fleshner, P.* ; Melmed, G.Y.* ; Vasiliauskas, E.A.* ; Ha, C.S.R.* ; Rabizadeh, S.* ; Syal, G.* ; Bonthala, N.N.* ; Ziring, D.A.* ; Targan, S.R.* ; Long, M.D.* ; McGovern, D.P.B.* ; International IBD Genetics Consortium (IIBDGC) (Gieger, C.)
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Gut 72, 2068-2080 (2023)
OBJECTIVE: Perianal Crohn's disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing CD subjects with and without perianal disease and subsequently performed functional follow-up studies for a pCD associated SNP in Complement Factor B (CFB). DESIGN: Immunochip-based meta-analysis on 4056 pCD and 11 088 patients with CD from three independent cohorts was performed. Serological and clinical variables were analysed by regression analyses. Risk allele of rs4151651 was introduced into human CFB plasmid by site-directed mutagenesis. Binding of recombinant G252 or S252 CFB to C3b and its cleavage was determined in cell-free assays. Macrophage phagocytosis in presence of recombinant CFB or serum from CFB risk, or protective CD or healthy subjects was assessed by flow cytometry. RESULTS: Perianal complications were associated with colonic involvement, OmpC and ASCA serology, and serology quartile sum score. We identified a genetic association for pCD (rs4151651), a non-synonymous SNP (G252S) in CFB, in all three cohorts. Recombinant S252 CFB had reduced binding to C3b, its cleavage was impaired, and complement-driven phagocytosis and cytokine secretion were reduced compared with G252 CFB. Serine 252 generates a de novo glycosylation site in CFB. Serum from homozygous risk patients displayed significantly decreased macrophage phagocytosis compared with non-risk serum. CONCLUSION: pCD-associated rs4151651 in CFB is a loss-of-function mutation that impairs its cleavage, activation of alternative complement pathway, and pathogen phagocytosis thus implicating the alternative complement pathway and CFB in pCD aetiology.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Ibd - Genetics ; Inflammatory Bowel Disease ; Meta-analysis
Keywords plus
Language
english
Publication Year
2023
Prepublished in Year
0
HGF-reported in Year
2023
ISSN (print) / ISBN
0017-5749
e-ISSN
1468-3288
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 72,
Issue: 11,
Pages: 2068-2080
Article Number: ,
Supplement: ,
Series
Publisher
BMJ Publishing Group
Publishing Place
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Institute of Epidemiology (EPI)
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-504091-004
Grants
Copyright
Erfassungsdatum
2024-03-05